ProteoMediX
Latest round
- Series C
Last raised
- Aug 2016
Total raised
- $13M
Investors
- 4
About ProteoMediX
Founded in 2010 and headquartered in Switzerland, ProteoMediX AG develops advanced diagnostic tests. The company has evolved its strategies over time but specific pivots are not documented. The co-founders, Christian Brühlmann and Ralph Schiess, have contributed their expertise to shape the firm’s direction. As of December 18, 2023, ProteoMediX AG became an acquisition target, acquired by Blue Water Biotech in an all-stock transaction for undisclosed financial terms.Proteomedix offers Proclarix®, a next-generation blood test specifically designed for diagnosing prostate cancer. This multiparametric test uses the same blood sample as the Prostate-Specific Antigen (PSA) test, eliminating the necessity for invasive biopsies. Proclarix is particularly beneficial for patients with PSA levels between 2-10 ng/ml, addressing a diagnostic grey zone where traditional testing often falls short.Proteomedix generates revenue primarily through the distribution of Proclarix® to diagnostic laboratories and healthcare providers. The company participates in direct business-to-business transactions, allowing laboratories to integrate Proclarix into their diagnostic services. Transactions typically involve bulk supply agreements or partnerships with healthcare institutions, focusing on affordability and accessibility within the healthcare sector., ProteoMediX AG is expected to leverage new resources for its growth strategy. The organization plans to expand its market presence and enhance its product offerings. Specific upcoming products have not been detailed, but there is an overall strategy for entering new geographic markets, particularly those with growing needs for prostate cancer diagnostics.
Who invested in ProteoMediX
4 investors across 4 rounds
See all investors in ProteoMediX
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about ProteoMediX
Who invested in ProteoMediX?
ProteoMediX has 4 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has ProteoMediX raised?
ProteoMediX has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did ProteoMediX last raise money?
ProteoMediX's most recent round on record is a Series C, in Aug 2016.
What does ProteoMediX do?
Founded in 2010 and headquartered in Switzerland, ProteoMediX AG develops advanced diagnostic tests.
Where is ProteoMediX headquartered?
ProteoMediX is headquartered in Switzerland.
Which VCs invest in companies like ProteoMediX?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back healthcare specialists companies at ProteoMediX's stage. Their profiles are linked below.
VCs backing healthcare specialists startups at Series C
Raising like ProteoMediX? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.